{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:57:12Z","timestamp":1776099432718,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.disamonth.2025.102012","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:56:05Z","timestamp":1758891365000},"page":"102012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multiple sclerosis updates and the safety and efficacy of Bruton tyrosine kinase inhibitors in it: A systematic review"],"prefix":"10.1016","volume":"71","author":[{"given":"Priyadarshi","family":"Prajjwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachi Vikrambhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeel Vishnubhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pugazhendi","family":"Inban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divyakshi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Mahato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laiba","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan Joseph Silva","family":"Godinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Tekuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2025.102012_bib0001","series-title":"Harrison's Principles of Internal Medicine, 20e","article-title":"Multiple sclerosis","author":"Cree","year":"2018"},{"key":"10.1016\/j.disamonth.2025.102012_bib0002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2377-13-128","article-title":"Incidence and prevalence of multiple sclerosis in Europe: a systematic review","volume":"13","author":"Kingwell","year":"2013","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.disamonth.2025.102012_bib0004","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.disamonth.2025.102012_bib0003","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.102012_bib0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: the devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.disamonth.2025.102012_bib0006","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.disamonth.2025.102012_bib0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.disamonth.2025.102012_bib0008","unstructured":"\u041d\u0430\u0443\u0447\u043d\u044b\u0439 \u0436\u0443\u0440\u043d\u0430\u043b European Journal of Natural History ISSN 2073-4972 \u0418\u0424 \u0420\u0418\u041d\u0426 = 0301 (n.d.) PATHOPHYSIOLOGY OF MULTIPLE SCLEROSIS - European Journal of Natural History (\u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0436\u0443\u0440\u043d\u0430\u043b). Available at: https:\/\/world-science.ru\/ru\/article\/view?id=34281 (Accessed: 19 April 2025)."},{"key":"10.1016\/j.disamonth.2025.102012_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.disamonth.2025.102012_bib0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","article-title":"The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms","volume":"26","author":"Engelhardt","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.disamonth.2025.102012_bib0011","doi-asserted-by":"crossref","unstructured":"Ortiz, G.G., Pacheco-Mois\u00e9s, F.P., Mac\u00edas-Islas, M.\u00c1., Flores-Alvarado, L.J., Mireles-Ram\u00edrez, M.A., Gonz\u00e1lez-Renovato, E.D., Hern\u00e1ndez-Navarro, V.E., S\u00e1nchez-L\u00f3pez,A.L., & Alatorre-Jim\u00e9nez, M.A. (2014). Role of the blood\u2013brain barrier in multiple sclerosis. Arch Med Res, 45(8), 687\u2013697. https:\/\/doi.org\/10.1016\/j.arcmed.2014.11.013","DOI":"10.1016\/j.arcmed.2014.11.013"},{"issue":"5","key":"10.1016\/j.disamonth.2025.102012_bib0012","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.disamonth.2025.102012_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.17116\/jnevro20221220725","article-title":"Mekhanizmy neirodegeneratsii pri rasseyannom skleroze [Mechanisms of Neurodegeneration in Multiple Sclerosis]","volume":"122","author":"Eliseeva","year":"2022","journal-title":"Zhurnal nevrologii i psikhiatrii imeni SS Korsakova"},{"issue":"3","key":"10.1016\/j.disamonth.2025.102012_bib0014","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3390\/ijms24031861","article-title":"Role of microglial cells in the pathophysiology of MS: synergistic or antagonistic?","volume":"24","author":"Mado","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.disamonth.2025.102012_bib0015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/cells8080825","article-title":"The molecular basis for remyelination failure in multiple sclerosis","volume":"8","author":"Gruchot","year":"2019","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.disamonth.2025.102012_bib0016","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awx113","article-title":"Loss of \u201chomeostatic\u201d microglia and patterns of their activation in active multiple sclerosis","volume":"140","author":"Zrzavy","year":"2017","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.disamonth.2025.102012_bib0017","first-page":"974","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"138","author":"Frischer","year":"2015","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.disamonth.2025.102012_bib0018","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple Sclerosis Pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.disamonth.2025.102012_bib0019","article-title":"A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis","volume":"17","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"10.1016\/j.disamonth.2025.102012_bib0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrn.2017.136","article-title":"Regenerating CNS myelin \u2014 From mechanisms to experimental medicines","volume":"18","author":"Franklin","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"10.1016\/j.disamonth.2025.102012_bib0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/nedt.2007.3.2.259","article-title":"Glatiramer acetate in the treatment of multiple sclerosis","volume":"3","author":"Tselis","year":"2007","journal-title":"Neuropsychiatr Dis Treatm"},{"issue":"3","key":"10.1016\/j.disamonth.2025.102012_bib0022","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in Multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.disamonth.2025.102012_bib0023","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in Multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.disamonth.2025.102012_bib0024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000001269","article-title":"Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations","volume":"37","author":"Kr\u00e4mer","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.disamonth.2025.102012_bib0025","article-title":"Bruton\u2019s tyrosine kinase and its isoforms in cancer","volume":"9","author":"Wang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.disamonth.2025.102012_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors and Autoimmune Diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.disamonth.2025.102012_bib0027","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/molecules28052400","article-title":"Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.disamonth.2025.102012_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.655489","article-title":"Reining in BTK: interdomain interactions and their importance in the regulatory control of BTK","volume":"9","author":"Kueffer","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.disamonth.2025.102012_bib0029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.021908.132541","article-title":"B cell signaling and fate decision","volume":"28","author":"Kurosaki","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.disamonth.2025.102012_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1129191","article-title":"NF\u03baB signaling in T cell memory","volume":"14","author":"Daniels","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.disamonth.2025.102012_bib0031","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0006-291X(02)00382-0","article-title":"Interaction of btk and akt in B cell signaling","volume":"293","author":"Lindvall","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.disamonth.2025.102012_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.694853","article-title":"Structure-function relationships of covalent and non-covalent BTK inhibitors","volume":"12","author":"Zain","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.disamonth.2025.102012_bib0033","first-page":"23","article-title":"Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis","volume":"32","author":"Shulga","year":"2023","journal-title":"Postepy psychiatrii neurologii"},{"key":"10.1016\/j.disamonth.2025.102012_bib0034","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.2147\/JIR.S389958","article-title":"The immunomodulatory functions of BTK inhibition in the Central nervous system","volume":"15","author":"Cao","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.disamonth.2025.102012_bib0035","unstructured":"myneuronews.com. (2025b, May 30). The role of microglia in multiple sclerosis: implications for treatment with Bruton\u2019s tyrosine kinase inhibitors. https:\/\/myneuronews.com\/2025\/05\/30\/the-role-of-microglia-in-multiple-sclerosis-implications-for-treatment-with-brutons-tyrosine-kinase-inhibitors"},{"key":"10.1016\/j.disamonth.2025.102012_bib0036","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12974-018-1308-0","article-title":"Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice","volume":"15","author":"Nam","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"11","key":"10.1016\/j.disamonth.2025.102012_bib0037","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11910-022-01229-z","article-title":"Bruton\u2019s tyrosine kinase inhibition in multiple sclerosis","volume":"22","author":"Schneider","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"10.1016\/j.disamonth.2025.102012_bib0038","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BPL-200100","article-title":"Bruton\u2019s tyrosine kinase inhibition promotes myelin repair","volume":"5","author":"Martin","year":"2019","journal-title":"Brain Plast"},{"issue":"20","key":"10.1016\/j.disamonth.2025.102012_bib0039","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.disamonth.2025.102012_bib0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of Rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.disamonth.2025.102012_bib0041","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2025.102012_bib0042","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241233041","article-title":"A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis","volume":"17","author":"Airas","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.disamonth.2025.102012_bib0043","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4","DOI":"10.1016\/S1474-4422(21)00237-4"},{"key":"10.1016\/j.disamonth.2025.102012_bib0044","article-title":"A study to evaluate the efficacy and safety of Fenebrutinib compared with teriflunomide in participants with relapsing multiple sclerosis (FENhance 1)","year":"2025","journal-title":"ClinicalTrials.gov"},{"key":"10.1016\/j.disamonth.2025.102012_bib0045","article-title":"A study to evaluate the efficacy and safety of Fenebrutinib compared with teriflunomide in participants with relapsing multiple sclerosis (FENhance 2)","year":"2025","journal-title":"ClinicalTrials.gov"},{"key":"10.1016\/j.disamonth.2025.102012_bib0046","article-title":"A study to evaluate the efficacy and safety of Fenebrutinib in participants with primary progressive multiple sclerosis (FENtrepid)","year":"2025","journal-title":"ClinicalTrials.gov"},{"key":"10.1016\/j.disamonth.2025.102012_bib0047","unstructured":"Novartis Pharmaceuticals. A study of remibrutinib compared with teriflunomide in participants with relapsing multiple sclerosis (REMODEL RMS 1). ClinicalTrials.gov. 2025. Accessed July 7, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05147220."},{"key":"10.1016\/j.disamonth.2025.102012_bib0048","unstructured":"Novartis Pharmaceuticals. A study of remibrutinib compared with teriflunomide in participants with relapsing multiple sclerosis (REMODEL RMS 2). ClinicalTrials.gov. Accessed July 7, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05156281"},{"key":"10.1016\/j.disamonth.2025.102012_bib0049","article-title":"A study to evaluate the efficacy and safety of Orelabrutinib in participants with relapsing-remitting multiple sclerosis","year":"2025","journal-title":"ClinicalTrials.gov"},{"issue":"4\u20135","key":"10.1016\/j.disamonth.2025.102012_bib0057","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/13524585241234783","article-title":"Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor Evobrutinib in relapsing multiple sclerosis: long-term follow-up of a phase II randomised clinical trial with a cerebrospinal fluid sub-study","volume":"30","author":"Montalban","year":"2024","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.disamonth.2025.102012_bib0052","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/cts.13162","article-title":"Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor Tolebrutinib (PRN2246, SAR442168)","volume":"15","author":"Owens","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.disamonth.2025.102012_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","article-title":"Characterisation of the safety profile of Evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis","volume":"94","author":"Montalban","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.disamonth.2025.102012_bib0059","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1177\/13524585221091060","article-title":"All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: no","volume":"28","author":"Rotstein","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.disamonth.2025.102012_bib0060","article-title":"Comparative CNS Pharmacology of the Brutons tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates For Treating Multiplesclerosis","author":"Turner","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.disamonth.2025.102012_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"20","key":"10.1016\/j.disamonth.2025.102012_bib0062","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.3390\/jcm11206139","article-title":"Bruton\u2019s tyrosine kinase inhibitors: the next frontier of B-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis","volume":"11","author":"Garg","year":"2022","journal-title":"J Clin Med"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001150292500166X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001150292500166X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T03:02:33Z","timestamp":1762398153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001150292500166X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S001150292500166X"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.102012","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple sclerosis updates and the safety and efficacy of Bruton tyrosine kinase inhibitors in it: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.102012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102012"}}